SARASOTA, Fla., April 09, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related conditions ...

Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced that Chief Medical Officer Dr. James Kelly ...

Oragenics Inc (NASDAQ:OGEN) shares are trading lower by 45.5% to $0.58 during Wednesday’s session after the company announced ...

SARASOTA, Fla. - Oragenics, Inc. (NYSE American: OGEN), a biotechnology firm focusing on brain health and infectious diseases, with a current market capitalization of $3.44 million, today ...

Explore Oragenics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for OGEN. EXCLUSIVE: Oragenics Completes Key FDA-Recognized Study For Concussion Drug ...

Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related conditions, today provided shareholders with an update on its ...

(MENAFN- Investor Brand Network) Oragenics (NYSE American: OGEN) reported significant strategic progress in Q1 2025 as it advances ONP-002, its intranasal concussion therapy, toward clinical Phase IIa ...